New York, May 23, 2026, 16:02 (EDT)
OPKO Health shares jumped during the holiday-shortened week, closing well above last Friday. The stock’s rebound looks better but remains shaky as U.S. markets prepare to open after Memorial Day.
Shares of the Miami-based biopharma and diagnostics firm finished Friday at $1.27, losing 0.8% for the day. The stock is still up about 15.5% from the May 15 close at $1.10. Trading volume came in around 3.16 million, topping volumes from earlier sessions in the week.
The market is shut for the weekend and U.S. exchanges stay closed Monday, May 25, for Memorial Day. Nasdaq calls it a full market closure, so trading picks up again Tuesday.
OPKO shares bounced without any new company news out in recent days. The most recent press release on the company’s investor page is from May 12, when its ModeX Therapeutics unit said it planned to present data on its in vivo CAR-T therapy, which engineers T cells inside the body.
Stocks moved up as the Nasdaq Composite edged 0.2% higher on Friday and finished the week up 0.5%. The Russell 2000 gained 2.7% for the week, the Associated Press reported. OPKO, valued at about $960 million, trades more like a small-cap healthcare stock than a big pharma company.
OPKO posted lower revenue for the first quarter at $124.2 million, compared to $149.9 million last year, but net loss came in at $54.8 million, or 7 cents a share, better than the $67.6 million, or 10 cents a share, loss reported a year ago. The company pointed to the BioReference asset sale in 2025 as the main reason for the revenue decline. Investors are looking at pipeline updates while weak revenue trends continue.
Mixed signals from peers and partners for OPKO. Pfizer is still a key player, since OPKO takes a share of gross profit from NGENLA, its long-acting human growth hormone. That contribution jumped to $6.4 million in Q1, up from $4.5 million a year ago. Labcorp also figures in the picture after it acquired certain BioReference oncology assets. That move took out $25.9 million in diagnostics revenue from OPKO’s comparison to last year.
ModeX keeps drawing investor interest on growth hopes. Chief scientific officer John Mascola pointed to May data that showed “strength of our in vivo targeting technology.” CEO Gary Nabel said the platform’s goal is to “generate CAR-T cells directly in patients.” Both executives were talking about animal model results, not human data. OPKO Health, Inc.
RAYALDEE is another focus for OPKO Health. Back in April, OPKO said its revised deal with Nicoya Therapeutics gives it 15% of Nicoya and leaves it in line for as much as $115 million in milestones for Greater China. OPKO Chairman and CEO Phillip Frost described China as “a major growth opportunity,” while Nicoya’s Leon Chen said possible approvals in China and nearby regions by 2027 would broaden patient access. OPKO Health, Inc.
The risk is still clear. OPKO spent more cash last quarter, with cash, cash equivalents, marketable securities and restricted cash down to $341.9 million at March 31, compared to $369.1 million at year-end. The company flagged that preclinical results might not hold up in clinical testing, and pointed to liquidity, regulatory and product-development risks. A failed trial, weak partner sales or another revenue miss could pull back last week’s share gains.
No regular trading Monday. OPKO’s next scheduled event is its 2026 annual stockholder meeting, June 18 at 10:00 a.m. EDT. Investors will be watching Tuesday’s open to see if last week’s move was just a brief pre-holiday uptick or a reset after the April earnings drag.
